What is the therapeutic effect of mifamurtide injection--Mepact?

Mifamurtide injection (trade name Mepact) is an immunomodulatory drug used to treat specific types of osteosarcoma, developed by Takeda Pharmaceutical (Takeda France SAS). The drug is mainly suitable for adjuvant treatment of high-grade, resectable, non-metastatic osteosarcoma in children, adolescents and young adults (age less than 30 years old) and needs to be used in combination with postoperative multi-drug chemotherapy. Its indications are based on clinical research data, and its safety and effectiveness have been verified in patients aged 2 to 30 years old.

In terms of efficacy, mivamutide activates macrophages and monocytes, promoting the release of a variety of cytokines, such as tumor necrosis factor (TNF-α) and interleukins (IL-1β, IL-6, etc.), thereby enhancing the body's immune killing effect on tumor cells. Clinical studies have shown that the combination of mivamutide and chemotherapy can significantly improve patient survival rates, especially for patients with osteosarcoma after complete surgical resection. The recommended dose is 2 intravenous injections for 12 weeks and then changed to 1 times a week, with a total treatment course of 36 weeks. This treatment regimen is designed to reduce the risk of tumor recurrence and improve long-term prognosis through sustained immune activation.

However, the use of mivamutide is also associated with some adverse effects. The most common adverse reactions include chills, pyrexia, fatigue, nausea, tachycardia, and headache. In addition, some patients may develop respiratory distress, neutropenia, or inflammatory reactions such as pericarditis and pleurisy. For patients with asthma or other chronic respiratory diseases, use with caution and preventive bronchodilators if necessary. People with cardiovascular disease also need to be closely monitored to prevent complications such as thrombosis or vasculitis. Allergic reactions, although uncommon, require caution, especially during the first dose.

Overall, mivamutin injection provides an effective adjuvant treatment option for specific osteosarcoma patients, and its immunomodulatory mechanism brings new hope for improving prognosis. However, its side effects and use restrictions in special populations require doctors to fully assess the patient's individual situation before treatment and closely monitor during treatment to ensure a balance between safety and efficacy. For Chinese patients, the drug has not yet been approved for marketing in China and must be obtained through specific channels, which also limits the popularity of its clinical application.

Reference link: https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf